These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30195276)

  • 1. [Clinical experience on a case of osteomyelitis treated with dalbavancin].
    Vates R; Rodríguez SJ; Martínez ME; Martínez JA
    Rev Esp Quimioter; 2018 Sep; ():. PubMed ID: 30195276
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study.
    Almangour TA; Perry GK; Alhifany AA
    Saudi Pharm J; 2020 Apr; 28(4):460-464. PubMed ID: 32273805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.
    Rappo U; Puttagunta S; Shevchenko V; Shevchenko A; Jandourek A; Gonzalez PL; Suen A; Mas Casullo V; Melnick D; Miceli R; Kovacevic M; De Bock G; Dunne MW
    Open Forum Infect Dis; 2019 Jan; 6(1):ofy331. PubMed ID: 30648126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility.
    Almangour TA; Perry GK; Terriff CM; Alhifany AA; Kaye KS
    Diagn Microbiol Infect Dis; 2019 Mar; 93(3):213-218. PubMed ID: 30396697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
    Silva V; Miranda C; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    Int J Antimicrob Agents; 2020 Jul; 56(1):106021. PubMed ID: 32439480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis.
    Boucher A; Pradier M; Lafondesmurs B; Thill P; Patoz P; Blondiaux N; Joulie D; Hennart B; Robineau O; Senneville E
    Infect Dis Now; 2024 Feb; 54(1):104835. PubMed ID: 37972818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current and future off-label uses of dalbavancin: a narrative review.
    De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
    Kussmann M; Obermueller M; Berndl F; Reischer V; Veletzky L; Burgmann H; Poeppl W
    Sci Rep; 2018 Jun; 8(1):9661. PubMed ID: 29941909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin.
    Loupa CV; Lykoudi E; Meimeti E; Moisoglou I; Voyatzoglou ED; Kalantzi S; Konsta E
    Med Arch; 2020 Jun; 74(3):243-245. PubMed ID: 32801445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
    McSorley JC; Reyes D; Tonna I; Bateman V
    Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience in the use of dalbavancin in diabetic foot infection.
    Navarro-Jiménez G; Fuentes-Santos C; Moreno-Núñez L; Alfayate-García J; Campelo-Gutierrez C; Sanz-Márquez S; Pérez-Fernández E; Velasco-Arribas M; Hervás-Gómez R; Martín-Segarra O; Losa-García JE
    Enferm Infecc Microbiol Clin (Engl Ed); 2022; 40(6):296-301. PubMed ID: 35490091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis.
    Barnea Y; Lerner A; Aizic A; Navon-Venezia S; Rachi E; Dunne MW; Puttagunta S; Carmeli Y
    J Antimicrob Chemother; 2016 Feb; 71(2):460-3. PubMed ID: 26518048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Dalbavancin Compared With Standard of Care for the Treatment of Osteomyelitis: A Real-world Analysis.
    Cain AR; Bremmer DN; Carr DR; Buchanan C; Jacobs M; Walsh TL; Moffa MA; Shively NR; Trienski TL
    Open Forum Infect Dis; 2022 Feb; 9(2):ofab589. PubMed ID: 35071682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
    Brescini L; Della Martera F; Morroni G; Mazzanti S; Di Pietrantonio M; Mantini P; Candelaresi B; Pallotta F; Olivieri S; Iencinella V; Castelletti S; Cocci E; Polo RG; Veccia S; Cirioni O; Tavio M; Giacometti A
    Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.
    Morata L; Cobo J; Fernández-Sampedro M; Guisado Vasco P; Ruano E; Lora-Tamayo J; Sánchez Somolinos M; González Ruano P; Rico Nieto A; Arnaiz A; Estébanez Muñoz M; Jiménez-Mejías ME; Lozano Serrano AB; Múñez E; Rodriguez-Pardo D; Argelich R; Arroyo A; Barbero JM; Cuadra F; Del Arco A; Del Toro MD; Guio L; Jimenez-Beatty D; Lois N; Martin O; Martínez Alvarez RM; Martinez-Marcos FJ; Porras L; Ramírez M; Vergas García J; Soriano A
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience in the use of dalbavancin in diabetic foot infection.
    Navarro-Jiménez G; Fuentes-Santos C; Moreno-Núñez L; Alfayate-García J; Campelo-Gutierrez C; Sanz-Márquez S; Pérez-Fernández E; Velasco-Arribas M; Hervás-Gómez R; Martín-Segarra O; Losa-García JE
    Enferm Infecc Microbiol Clin (Engl Ed); 2021 Jan; ():. PubMed ID: 33451810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.